EPO and neoplasm: Hypoxia is a known hallmark of radioresistance; thus, researchers predict that elevated endogenous erythropoietin levels may be used as a hypoxia marker, causing the tumor to become more aggressive and perhaps impairing treatment effects (Lazzari and Silvano 2020).